Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VERVE-102 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 2: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 3: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 4: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 5: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 6: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 7: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 8: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 9: Single Fixed Dose | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 10: Single Fixed Dose | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Name | Type | Description |
|---|---|---|
| VERVE-102 | DRUG | Intravenous (IV) infusion |
Inclusion Criteria: * Diagnosis of HeFH or premature CAD Exclusion Criteria: * Homozygous familial hypercholesterolemia * Active or history of chronic liver disease * Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe * Clinically significant or abnormal laborato...
VERVE-102 is an investigational small molecule being developed for the treatment of heterozygous familial hypercholesterolemia, a genetic condition that causes high cholesterol. It is also being studied in patients with premature coronary artery disease. The drug is currently in Phase 1 clinical development.
VERVE-102 targets the PCSK9 gene. By targeting this gene, the drug is designed to address the underlying genetic cause of elevated cholesterol levels in patients with heterozygous familial hypercholesterolemia. The drug is a small molecule that acts on this gene target.
VERVE-102 is being developed by Verve Therapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol VERV. Verve Therapeutics is conducting clinical trials to evaluate the safety and efficacy of VERVE-102 in patients with familial hypercholesterolemia.
VERVE-102 is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The Phase 1 trial is currently recruiting participants to evaluate the drug's safety, tolerability, and effects in patients with heterozygous familial hypercholesterolemia or premature coronary artery disease.
VERVE-102 is being studied in a Phase 1 clinical trial registered as NCT06164730. This trial is titled 'A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease' and is currently recruiting. The study is enrolling approximately 85 participants across multiple countries, including the United States, Australia, Canada, Israel, New Zealand, and the United Kingdom.
VERVE-102 is a distinct investigational drug that targets the PCSK9 gene. It is a small molecule designed to act on this gene, which differentiates it from other PCSK9-targeting therapies. The drug is being developed specifically for heterozygous familial hypercholesterolemia and is currently in Phase 1 clinical trials.